413 / 1068
The Royal Marsden
Secondary endpoints
1.
Time to local re-growth.
2.
Time to maximal tumour response after CRT
3.
Time to local pelvic relapse, pre or post surgery.
4.
Time to metastatic relapse, pre or post surgery.
5.
Percentages of positive margins, and sphincter-preservation rates in patients who have
had surgery. Pathology T N stage.
6.
Progression-free and overall survival
7.
Quality of Life including long-term bowel and urinary function
8.
Probability of detecting early re-growth on MRI at 16 weeks, 24 weeks and 9 months.
9.
Report on proportion of patients eligible at 12 weeks compared to eligible at 6 weeks.
10.
Frequency of local re-growth detected outside scheduled imaging/endoscopic timepoint
by DRE/CEA.